SCHEMBL17520362

SCHEMBL17520362

COc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCn1ccnc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EGFR P00533 19/20 1.00
KDR P35968 3/20 0.77
FGFR1 P11362 1/20 0.77
FLT1 P17948 1/20 0.77
AURKA O14965 1/20 0.71
ERBB2 P04626 1/20 0.71
INSR P06213 1/20 0.71
FBP1 P09467 1/20 0.71
PDGFRB P09619 1/20 0.71
FLT4 P35916 1/20 0.71
CLK1 P49759 1/20 0.71
EPHB4 P54760 1/20 0.71
TEK Q02763 1/20 0.71
AURKB Q96GD4 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11156 1.00 EGFR (1.00) EGFRKDRFGFR1FLT1AURKA
SCHEMBL11683 0.96 EGFR (0.92) EGFRKDRFGFR1FLT1AURKA
SCHEMBL18979111 0.96 EGFR (0.92) EGFRKDRFGFR1FLT1AURKA
SCHEMBL19220785 0.90 EGFR (0.82) EGFRKDRFGFR1FLT1AURKA
SCHEMBL12856430 0.89 EGFR (0.80) EGFRKDRFGFR1FLT1ERBB2
SCHEMBL7451584 0.87 FLT1 (1.00) EGFRKDRFGFR1FLT1PDGFRB
Hydrochloric Acid SCHEMBL7455267 0.86 FLT1 (0.98) EGFRKDRFGFR1FLT1PDGFRB
SCHEMBL19220767 0.86 EGFR (0.76) EGFRKDRFGFR1FLT1ERBB2
SCHEMBL13524614 0.85 EGFR (0.87) EGFRKDRAURKAERBB2INSR
SCHEMBL30520472 0.85 EGFR (0.87) EGFRKDRAURKAERBB2INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 EP disclosed
US-10774079-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2020-09-15 US disclosed
CN-106660970-B Quinazoline derivatives 石药集团中奇制药技术(石家庄)有限公司 2020-07-10 CN disclosed
US-10421754-B2 Quinazoline derivative CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2019-09-24 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
EP-3181554-A1 QUINAZOLINE DERIVATIVE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-06-21 EP disclosed
WO-2016023330-A1 QUINAZOLINE DERIVATIVE 石药集团中奇制药技术(石家庄)有限公司 2016-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774079-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885
US-10421754-B2 Quinazoline derivative H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885FGFR1 4724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.